Jade Biosciences, Inc. Deferred Offering Costs
Jade Biosciences, Inc. (JBIO) had Deferred Offering Costs of $14.55 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-08-10
- 2026-06-30: Deferred Offering Costs $14.55K.
- 2025-12-31: Deferred Offering Costs $15.89M.
- 2025-09-30: Deferred Offering Costs $14.55M.
- 2025-06-30: Deferred Offering Costs $14.55K; Deferred Offering Costs as first filed $14.55M.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2026-06-30 | $14.55K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $15.89M 10-K · filed 2026-03-06 | |
| 2025-09-30 | $14.55M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $14.55K 10-Q · filed 2026-08-10 | $14.55M 10-Q · filed 2025-08-13 |
| 2021-06-30 | $297.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |